Phenylketonuria natural history, complications and prognosis: Difference between revisions

Jump to navigation Jump to search
m (Categories)
 
(3 intermediate revisions by one other user not shown)
Line 2: Line 2:
{{Phenylketonuria}}
{{Phenylketonuria}}
{{CMG}}; {{AE}}
{{CMG}}; {{AE}}
==Overview==
==Overview==
==Natural History==
==Natural History==
If a child is not screened at birth (e.g. in home deliveries), the disease may present clinically with [[seizure]]s, [[albinism]] (excessively fair hair and skin), and a "musty odor" to the baby's sweat and urine (due to [[phenylacetate]], one of the ketones produced).  
If a child is not screened at birth (e.g. in home deliveries), the disease may present clinically with [[seizure]]s, [[albinism]] (excessively fair hair and skin), and a "musty odor" to the baby's sweat and urine (due to [[phenylacetate]], one of the ketones produced).  
Line 16: Line 18:


==Prognosis==
==Prognosis==
Well controlled and early diagnosed PKU has a great prognosis, but it requires a life long dietary restriction and ingestion of amino acid supplement.  
Well controlled and early diagnosed PKU has a great prognosis, but it requires a life long dietary restriction and ingestion of amino acid supplement.<ref name="pmid22475869">{{cite journal| author=Macleod EL, Ney DM| title=Nutritional Management of Phenylketonuria. | journal=Ann Nestle Eng | year= 2010 | volume= 68 | issue= 2 | pages= 58-69 | pmid=22475869 | doi=10.1159/000312813 | pmc=PMC2901905 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22475869  }} </ref>
 
On the other hand, when patients with PKU do not receive treatment, the prognosis is poor, and it greatly affects the neurologic system and intellectual capacity.<ref name="pmid26084935">{{cite journal| author=Bosch AM, Burlina A, Cunningham A, Bettiol E, Moreau-Stucker F, Benmedjahed K et al.| title=Assessment of the impact of phenylketonuria and its treatment on quality of life of patients and parents from seven European countries. | journal=Orphanet J Rare Dis | year= 2015 | volume= 10 | issue= 1 | pages= 80 | pmid=26084935 | doi=10.1186/s13023-015-0294-x | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26084935  }} </ref>


==References==
==References==
{{Reflist|2}}


{{Reflist|2}}
[[Category:Metabolic disorders]]
[[Category:Genetic disorders]]
[[Category:Congenital disorders]]
[[Category:Pediatrics]]
[[Category:Pediatrics]]
[[Category:Neurology]]
[[Category:Neurology]]
[[Category:Metabolism]]
[[Category:Endocrinology]]
[[Category:Inborn errors of metabolism]]
 
{{WS}}
{{WH}}

Latest revision as of 13:12, 26 July 2016

Phenylketonuria Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Phenylketonuria from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Phenylketonuria On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Phenylketonuria

All Images
X-ray X-rays
Ultrasound Echo & Ultrasound
CT CT Images
MRI MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Phenylketonuria

CDC on Phenylketonuria

Phenylketonuria in the news

Blogs on Phenylketonuria

Directions to Hospitals Treating Phenylketonuria

Risk calculators and risk factors for Phenylketonuria

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Natural History

If a child is not screened at birth (e.g. in home deliveries), the disease may present clinically with seizures, albinism (excessively fair hair and skin), and a "musty odor" to the baby's sweat and urine (due to phenylacetate, one of the ketones produced).

Untreated children are normal at birth, but fail to attain early developmental milestones, develop microcephaly, and demonstrate progressive impairment of cerebral function. Hyperactivity, EEG abnormalities and seizures, and severe mental retardation are major clinical problems later in life. A "musty" odor of skin, hair, sweat and urine (due to phenylacetate accumulation); and a tendency to hypopigmentation and eczema are also observed.

In contrast, affected children who are detected and treated at birth are less likely to develop neurological problems and have seizures and mental retardation, though such clinical disorders are still possible.

Complications

Complications are seen both in treated and untreated patients, but are more frequently seen in the second group, and in the patients that are lately diagnosed.

Neurocognitive aspects such as IQ, processing speed, attention, inhibition, and motor control can be affected, PKU is also associated with low self-esteem,lower achievement motivation, decreased autonomy, decreased social competence,  and possible increased risk for depressed mood, generalized anxiety and social isolation.[1]

Prognosis

Well controlled and early diagnosed PKU has a great prognosis, but it requires a life long dietary restriction and ingestion of amino acid supplement.[2]

On the other hand, when patients with PKU do not receive treatment, the prognosis is poor, and it greatly affects the neurologic system and intellectual capacity.[3]

References

  1. Regnault A, Burlina A, Cunningham A, Bettiol E, Moreau-Stucker F, Benmedjahed K; et al. (2015). "Development and psychometric validation of measures to assess the impact of phenylketonuria and its dietary treatment on patients' and parents' quality of life: the phenylketonuria - quality of life (PKU-QOL) questionnaires". Orphanet J Rare Dis. 10 (1): 59. doi:10.1186/s13023-015-0261-6. PMID 25958326.
  2. Macleod EL, Ney DM (2010). "Nutritional Management of Phenylketonuria". Ann Nestle Eng. 68 (2): 58–69. doi:10.1159/000312813. PMC 2901905. PMID 22475869.
  3. Bosch AM, Burlina A, Cunningham A, Bettiol E, Moreau-Stucker F, Benmedjahed K; et al. (2015). "Assessment of the impact of phenylketonuria and its treatment on quality of life of patients and parents from seven European countries". Orphanet J Rare Dis. 10 (1): 80. doi:10.1186/s13023-015-0294-x. PMID 26084935.

Template:WS Template:WH